Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J. · 2017
Read Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. by Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5746170.txt.
Description
Coelho and co-authors study how RAS, a cancer driving signal, helps tumors hide from immunity. Many cancers raise PD-L1, a protein that damps immune attack. Whether that rise comes from the tumor cells or their setting was unclear. The team traced the path inside cancer cells.
RAS signaling steadies the PD-L1 message, they find, by blocking its destroyer. That destroyer is tristetraprolin, which binds a rich zone in the message tail. A kinase under RAS switches tristetraprolin off. Human lung and bowel tumors with active RAS show higher PD-L1. Restoring tristetraprolin in mice boosted anti-tumor immunity.
Catalog record
| CREATOR | Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |